3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
17
Liposarcoma
3
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Leiomyosarcoma
2
Breast Neoplasms
2
Solitary Fibrous Tumors
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neoplasm Metastasis
1
Melanoma
1
Histiocytoma, Malignant Fibrous
1
Hemangiosarcoma
1
Hemangioendothelioma, Epithelioid
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Interventions
pazopanib
2
Ifosfamide
2
Doxorubicin
2
selinexor
1
repotrectinib
1
pembrolizumab
1
eribulin
1
Trabectedin
1
Suspensions
1
Sunitinib
1
Proton Therapy
1
Nivolumab
1
Methotrexate
1
Magnetic Resonance Spectroscopy
1
Histamine H2 Antagonists
1
Fluorodeoxyglucose F18
1
Famotidine
1
FAPI-46
1
Epirubicin
1
Dasatinib
1
Dacarbazine
1
Cisplatin
1
Capsules
1
Angptl4 protein, mouse
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Solitary Fibrous Tumors
×
eribulin
×
Sarcoma
×
Clear all
NCT03840772
2024-09-20
ERASING
Italian Sarcoma Group
Phase 2
Completed
16 enrolled